SUCCESSFUL MOBILIZATION WITH AMD3100 AND FILGRASTIM WITH ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN A HEAVILY PRETREATED PEDIATRIC PATIENT WITH RECURRENT BURKITT LYMPHOMA

REFERENCES

• Cottler-Fox MH, Lapidot T, Petit I, Stem Cell Mobilization. Hematology 2003. ASH Education Program Book; 2003:419–438.
   Google Scholar
• Cashen A, Lopez S, Gao F, A phase II study of Plerixafor (AMD3100) plus G-SCF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1253–1261.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Pearce R, Hartmann O, High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood. 1997;90:2921–2930.
   PubMed Web of Science ®Google Scholar
• Griffin T, Weitzman S, Weinstein H, A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic luekemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52:177–181.
   PubMed Web of Science ®Google Scholar
• Philip T, Hartmann O, Pinkerton R, Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d’Oncologie Pediatrique. Blood. 1993;80:2003–2006.
   Google Scholar
• Cairo MS, Sposto R, Perkins SL, Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol. 2003;120:660–670.
   PubMed Web of Science ®Google Scholar
• Kobrinsky N, Sposto R, Shah N. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintence chemotherapy and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol. 2001;19:2390–2396.
   PubMed Web of Science ®Google Scholar
• Weaver CH, Birch R, Greco FA, Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol. 1998;2:338–347.
   Google Scholar
• Halle P, Kanold J, Rapatel C, Granulocyte colony-stimulating factor alone at 20 micrograms/kg vs 10 micrograms/kg for peripheral blood stem cell mobilization in children. Pediatr Transplant 2000;4:285–288.
   Google Scholar
• Sevilla J, Gonzalez-Vicent M, Madero F, Madero L, Granulocyte colony-stimulating factor alone at 12 μg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplant. 2002;30:471–420.
   Google Scholar
• Merlin E, Piguet C, Auvirgnon A, The pros and cons of split-dose granulocyte colony-stimulating factor alone rather than a single high dose for hematopoietic cell mobilization in small children (<15 kg) with solid tumors. Hematologica. 2006;91:1004–1005.
   Google Scholar
• To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997;89:2233–2258.
   PubMed Web of Science ®Google Scholar
• Korbling M, Flietner T. History of stem cell transplants. In: Gale RP, Juttner C, Henon P, eds. Blood Stem Cell Transplants. New York: Cambridge University Press; 1994:9–19.
   Google Scholar
• Narayanasami U, Kanteti R, Morelli J, Randomized trial of filgrastim versus chemotherapy and filgrastim of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001;98:2059–2064.
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landau S, Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045–1056.
   PubMed Web of Science ®Google Scholar
• Okada S, Hongo T, Sakaguchi K, Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem mobilization in patients with high-risk or relapsed medulloblastoma. Childs Nerv Syst. 2007;23:407–413.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak ML, Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588–1593.
   PubMed Web of Science ®Google Scholar
• Stewart D, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009;15:39–46.
   PubMed Web of Science ®Google Scholar
• Beyer J, Schwella N, Zingsem J, Hematopoietic rescue after high-dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol. 1995;13:1328–1335.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Dreger P, Linch DC. Randomized trial of filgrastim-mobilized peripheral blood progenitior cell transplantation versus autologous bone-marrow transplant in lymphoma patients. Lancet. 1996;347:353–357.
   PubMed Web of Science ®Google Scholar
• Broxmeyer H, DiPersio J, Flomenberg N. Symposium report. Blood Marrow Transplant Rev. 2005;15:4–10.
   Google Scholar
• Voermans C, Kooi ML, Rodenhuis S, In vitro migratory capacity of CD34++ cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood. 2001;97:799–804.
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Liu Q. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34++ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells. 2001;19:37–45.
   PubMed Web of Science ®Google Scholar
• Flomberg N, Devine S, DiPersio J, The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor mobilization is superior to G-CSF alone. Blood. 2005;106:1867–1874.
   Google Scholar
• Robertson KA, Pradhan K, Goebel S, Mobilization of peripheral CD34+ stem cells in a heavily pre-treated pediatric medulloblastoma patient. Biol Blood Marrow Transplant. 2006;12:75–76.
   Google Scholar
• McGuirk J, Ginn K, Badel K. AMD3100 plus G-CSF use in proven poor mobilizers in a compassionate use protocol. Blood. 2005;106:49a.
   Google Scholar
• Calandra, G, McCarty J, McGuirk J, AMD plus G-CSF can successfully mobilize CD34++ cells from non-Hodgkin's lymphoma, Hodgkin's disease, and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41:331–338.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Levy V, Makke J, Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure. Haematologica. 2004;89:1532–1534.
   Google Scholar
• Weaver CH, Tauer K, Zhen B. Second attempts at mobilization of peripheral stem blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998;3:241–249.
   Google Scholar
• Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43–52.
   PubMed Web of Science ®Google Scholar
• Nervi B, Ramirez P, Rettig M, Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR antagonist AMD3100. Blood. 2009;113:6206–6214.
   PubMed Web of Science ®Google Scholar
• FDA Summary. 12 December 2008. Retrieved 12 April 2009 from: accessdata.fda.gov/ drugsatfda_docs/nda/2008/022311s000_SumR.pdf:4-5.
   Google Scholar
• Hendrix CW, Collier AC, Lederman MM, Safety, pharmacokinetics and antiviral activity of AMD3100, a selective CXCR-4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37:1253–1262.
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Flexner C, MacFarland RT, Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor in human volunteers. Antimicrob Agents Chemother. 44:1667–1673.
   Google Scholar
• FDA Approval Letter. 12 December 2008. Retrieved 12 April 2009 from: www.fda.gov/cder/ foi/appletter/2008/022311s000ltr.pdf
   Google Scholar